A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

Trial Profile

A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Cat SPIRE (Primary)
  • Indications Allergic rhinoconjunctivitis; Perennial allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Acronyms CATALYST
  • Sponsors Circassia
  • Most Recent Events

    • 25 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 22 Apr 2016 The trial was prematurely ended in Lithuania, Latvia and Estonia; completed in Poland (end date: 2016-02-02).
    • 06 Jun 2015 Planned number of patients changed from 1182 to 1400, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top